When to Perform Anal Pap Smear Screening
Anal Pap smears should be performed in HIV-infected men who have sex with men (MSM), HIV-infected women with a history of receptive anal intercourse or abnormal cervical Pap tests, and all HIV-infected persons with genital warts. 1
Primary Indications for Anal Pap Screening
HIV-Infected Populations (Established Guidelines)
The 2014 HIV Medicine Association guidelines provide clear recommendations for anal cancer screening 1:
- HIV-infected MSM - These patients face the highest risk for anal dysplasia and cancer due to HPV infection
- HIV-infected women with:
- History of receptive anal intercourse
- Abnormal cervical Pap test results
- All HIV-infected persons with genital warts regardless of sexual practices
Important caveat: While these guidelines recommend anal Pap testing for these groups, they note this is a "weak recommendation with moderate quality evidence," reflecting that the evidence base in 2014 was still developing 1.
Expanded Risk Groups (Recent Consensus)
The 2024 International Anal Neoplasia Society guidelines provide more comprehensive, risk-stratified recommendations 2:
Highest priority screening (start at age 35):
- MSM with HIV
- Transgender women with HIV
Moderate priority screening (start at age 45):
- People with HIV (regardless of sexual practices)
- MSM without HIV
- Transgender women without HIV
Additional populations to consider (start at age 45 or condition-specific timing):
- Solid organ transplant recipients (begin 10 years post-transplant)
- Persons with history of vulvar precancer or cancer (within 1 year of diagnosis)
- Persons ≥45 years with:
- History of cervical/vaginal HSIL or cancer
- Perianal warts
- Persistent (>1 year) cervical HPV16
- Autoimmune conditions
Clinical Algorithm for Decision-Making
Step 1: Identify HIV status
- If HIV-positive → Proceed to Step 2
- If HIV-negative → Proceed to Step 3
Step 2: For HIV-positive patients, assess:
- MSM or transgender women? → Screen starting at age 35 2
- Women with receptive anal intercourse history or abnormal cervical Pap? → Screen 1
- Presence of genital warts? → Screen 1
- None of the above? → Screen starting at age 45 2
Step 3: For HIV-negative patients, assess:
- MSM or transgender women? → Screen starting at age 45 2
- Solid organ transplant recipient? → Screen starting 10 years post-transplant 2
- History of vulvar precancer/cancer? → Screen within 1 year of diagnosis 2
- Age ≥45 with cervical/vaginal HSIL, perianal warts, persistent HPV16, or autoimmune conditions? → Consider screening with shared decision-making 2
Follow-Up After Abnormal Results
When anal cytology screening identifies abnormal findings, high-resolution anoscopy (HRA) should be performed with biopsy of abnormal areas 1. This is critical because cytology alone is a poor predictor of lesion severity 3.
Key Pitfalls to Avoid
Don't screen the general population: The low prevalence of anal cancer in the general population makes routine screening inappropriate 4, 5. Screening must be targeted to high-risk groups.
Don't rely on HPV testing alone for primary screening: HPV testing in MSM populations leads to excessive false positives due to the extremely high prevalence of HPV infection in this group 3. Cytology remains the preferred primary screening modality.
Don't assume screening guidelines are universally accepted: As of 2014, no national health care organizations recommended routine anal Pap screening even for high-risk groups 5. The 2024 IANS guidelines 2 represent the most recent consensus effort to address this gap, but implementation may vary by institution and provider capacity to perform HRA.
Ensure HRA capacity exists: The 2024 guidelines emphasize that screening should only be offered when adequate capacity exists to perform diagnostic HRA procedures 2, as screening without the ability to follow up abnormal results appropriately is not beneficial.